About Dr. Saleh A. Naser
We investigate the association of Mycobacterium avium subspecies paratuberculosis (MAP) with Crohn’s disease and Type I Diabetes based on molecular mimicry
The overall objective of our research program is to investigate the role of Mycobacterium avium subsp. paratuberculosis (MAP) in the etiology of Crohn’s disease and Type I Diabetes.
- Diagnosis: we developed nested PCR assay and have identified biomarkers to predict the presence of MAP in clinical samples.
- Pathogenesis: We are investigating MAP role in Crohn’s and Type I Diabetes in association with single nucleotide polymorphisms (SNPs) in disease-specific genes.
- Treatment: Our lab is the focal point in an international phase III clinical trial to treat Crohn’s patients with anti-MAP therapy.
- Funding: Our research program is currently funded from various sources.
Publications since 2014:
|Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
A Qasem, S Ramesh, SA Naser. 2018. BMJ Open Gastroenterology 6 (1), e000246
|Development of multiplex PCR and multi-color fluorescent in situ hybridization (m-FISH) coupled protocol for detection and imaging of multi-pathogens involved in inflammatory …
RC Sharp, ES Naser, KP Alcedo, A Qasem, LS Abdelli, SA Naser. 2018. Gut pathogens 10 (1), 51
|Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
BL Cao, A Qasem, RC Sharp, LS Abdelli, SA Naser. 2018. World journal of gastroenterology 24 (25), 2764
|TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn’s disease to current approved therapy
A Qasem, SA Naser. 2018. BMJ open gastroenterology 5 (1), e000216
|When old metagenomic data meet newly sequenced genomes, a case study
X Li, SA Naser, A Khaled, H Hu, X Li. 2018. PloS one 13 (6), e0198773
|Pathophysiology of rheumatoid arthritis is associated with polymorphisms in Protein Tyrosine Phosphatase Non-receptor type 2 and 22 (PTPN2/22) and susceptibility to Mycobacteria
RC Sharp, SA Beg, SA Naser. 2018. The Journal of Immunology 200 (1 Supplement), 166.12-166.12
|Role of TNFα Antagonists in Susceptibility to Mycobacterial Infection in Association with Genetic Polymorphisms in Crohn’s Disease
A Qasem, S Naser. 2018. The Journal of Immunology 200 (1 Supplement), 45.14-45.14
|Mycobacterial infection influences bone biomarker levels in patients with Crohn’s disease
A Naser, A Qasem, SA Naser. 2018. Canadian journal of physiology and pharmacology 96 (7), 662-667
|Oleuropein is responsible for the major anti-inflammatory effects of olive leaf extract
K Qabaha, F AL-Rimawi, A Qasem, SA Naser. 2018. Journal of medicinal food 21 (3), 302-305
|Role of PTPN2/22 polymorphisms in pathophysiology of Crohn’s disease
RC Sharp, SA Beg, SA Naser. 2018. World Journal of Gastroenterology 24 (6), 657
|Inflammatory diseases of the gut
M Rohr, CA Narasimhulu, D Sharma, M Doomra, A Riad, S Naser. 2018. Journal of medicinal food 21 (2), 113-126
|Polymorphisms in protein tyrosine phosphatase non-receptor type 2 and 22 (PTPN2/22) are linked to hyper-proliferative T-Cells and susceptibility to mycobacteria in rheumatoid
RC Sharp, SA Beg, SA Naser. 2018. Frontiers in cellular and infection microbiology 8, 11
For all the articles, you may find them at this link: Articles List